FDA Approves Dupilumab (Dupixent) for Eczema FDA Approves Dupilumab (Dupixent) for Eczema

Designated a breakthrough therapy, dupilumab spares patients with moderate to severe eczema from the need to resort to systemic immunosuppressants and the higher risks they pose.FDA Approvals

Source: Medscape Dermatology Headlines - March 28, 2017 Category: Dermatology Tags: Dermatology News Alert Source Type: news